ArticleScientific reports2026
A machine learning predictive model for staging chronic hepatitis B inflammation based on non-invasive metrics.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Early screening and antiviral therapy for significant liver inflammation in chronic hepatitis B (CHB) remain significant barriers as the key to disease reversal. The aim of this study was to develop a machine learning predictive model based on clinically available hematological indicators to assess liver inflammation in patients with CHB. This multicentre retrospective study comprised patients with untreated CHB who underwent hepatic puncture biopsy from 2014 to 2022. The best features were screened by the Gini index and Lasso. The machine learning model with the highest diagnostic performance for apparent liver inflammation was selected by comprehensive evaluation of parameters such as area under the receiver operating characteristic curve (AUROC) and decision curve analysis. This study included a total of 1,592 patients with chronic hepatitis B (CHB). Four indicators were ultimately selected: aspartate transaminase (AST), gamma-glutamyl transpeptidase (GGT), alpha-fetoprotein (AFP), and albumin-globulin ratio (AGR), which were used to construct the AAAG model. The model's AUROC value ranged from 0.79 to 0.84, particularly in female patients, where the AUROC value reached 0.85 to 0.88. Additionally, a publicly available online tool was developed for assessing liver inflammation. A simple, non-invasive tool with good diagnostic value for assessing significant liver inflammation in patients with chronic hepatitis B for early screening was developed and validated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.